Back to top
more

AbbVie (ABBV)

(Delayed Data from NYSE)

$173.61 USD

173.61
4,066,881

+1.29 (0.75%)

Updated Jul 22, 2024 04:00 PM ET

After-Market: $173.95 +0.34 (0.20%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 28% (181 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.

Q2 Earnings in Full Swing This week

by Zacks Equity Research

Q2 Earnings in Full Swing This week.

Mark Vickery headshot

First Full Week of Q2 Earnings, PCE Out Friday

by Mark Vickery

No fewer than 845 companies are scheduled to report this week, including Alphabet (GOOGL) and Tesla (TSLA) Tuesday.

Sundeep Ganoria headshot

AbbVie (ABBV) Stock Before Q2 Earnings: To Buy or Not to Buy?

by Sundeep Ganoria

Investor focus will likely be on sales of AbbVie's (ABBV) blockbuster immunology drugs Rinvoq and Skyrizi when it reports second-quarter results.

AbbVie (ABBV) Rises As Market Takes a Dip: Key Facts

by Zacks Equity Research

AbbVie (ABBV) closed at $172.32 in the latest trading session, marking a +0.69% move from the prior day.

Kinjel Shah headshot

Pharma Stock Roundup: JNJ, NVS Q2 Earnings, RHHBY's Positive Obesity Pill Data

by Kinjel Shah

J&J (JNJ) and Novartis (NVS) beat estimates for earnings and sales. Roche's (RHHBY) oral weight loss GLP-1 therapy achieves positive results in an early-stage study.

Earnings Preview: AbbVie (ABBV) Q2 Earnings Expected to Decline

by Zacks Equity Research

AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Syros (SYRS) Stock Rises More Than 35% in 3 Months: Here's Why

by Zacks Equity Research

Syros (SYRS) is progressing well with the development of its pipeline candidate, tamibarotene, which is being studied for two different cancer indications.

AbbVie (ABBV) Files for Rinvoq in Giant Cell Arteritis in US & EU

by Zacks Equity Research

AbbVie (ABBV) files regulatory applications to the FDA and the EMA, seeking approval for a new indication of Rinvoq, giant cell arteritis.

AbbVie (ABBV) Gains As Market Dips: What You Should Know

by Zacks Equity Research

The latest trading day saw AbbVie (ABBV) settling at $169.91, representing a +1.05% change from its previous close.

Kinjel Shah headshot

AbbVie (ABBV) Up 24% in a Year: Buy, Sell or Hold the Stock?

by Kinjel Shah

Investors who own AbbVie's (ABBV) stock may stay invested as the company has faced its biggest challenge, Humira's patent cliff- quite well and looks set to return to robust growth next year.

Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock

by Zacks Equity Research

Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

The Zacks Analyst Blog Highlights Novo Nordisk, AbbVie, AstraZeneca, Air T and United-Guardian

by Zacks Equity Research

Novo Nordisk, AbbVie, AstraZeneca, Air T and United-Guardian are included in this Analyst Blog.

Mark Vickery headshot

Top Stock Reports for Novo Nordisk, AbbVie & AstraZeneca

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S (NVO), AbbVie Inc. (ABBV) and AstraZeneca PLC (AZN), as well as two micro-cap stocks, Air T, Inc. (AIRT) and United-Guardian, Inc. (UG).

Should First Trust Morningstar Dividend Leaders ETF (FDL) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for FDL

Eli Lilly (LLY) to Buy Morphic for $3.2B, Boost IBD Presence

by Zacks Equity Research

Eli Lilly's (LLY) acquisition of Morphic (MORF) is set to expand its immunology pipeline by adding the latter's lead candidate, MORF-057, which is being developed for IBD conditions.

How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks

by Zacks Equity Research

The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?

Company News for Jul 3, 2024

by Zacks Equity Research

Companies in The News Are: TSLA, AAPL, IQ, ABBV

AbbVie (ABBV) Gets CHMP Nod for Lymphoma Drug's Expanded Use

by Zacks Equity Research

AbbVie (ABBV) is seeking approval for Tepkinly in the EU as a monotherapy for the treatment of adult patients with relapsed/refractory follicular lymphoma after two or more prior therapies.

Merck (MRK) Gets CHMP Nod for PAH Drug Winrevair in Europe

by Zacks Equity Research

Merck's (MRK) Winrevair is poised to become the first activin signaling inhibitor therapy for PAH in Europe if approved by the European Commission.

Kinjel Shah headshot

Pharma Stock Roundup: FDA's CRL to MRK & ABBV, Phase III Study Failures for NVO, AZN

by Kinjel Shah

FDA rejects Merck (MRK) and AbbVie's (ABBV) filings for pipeline candidates. AstraZeneca (AZN) and Novo Nordisk (NVO) announce study failures.

AbbVie's (ABBV) Celsius Therapeutics Deal to Boost IBD Presence

by Zacks Equity Research

AbbVie's (ABBV) acquisition of Celsius Therapeutics is set to add the latter's lead pipeline candidate, CEL383, a potential first-in-class TREM1 inhibitor, to ABBV's pipeline.

Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for PJP

FDA Expands AbbVie's (ABBV) Epkinly Label in Follicular Lymphoma

by Zacks Equity Research

Following the label expansion, AbbVie's (ABBV) Epkinly is the first bispecific antibody approved to treat relapsed/refractory (R/R) follicular lymphoma and R/R diffuse large B-cell lymphoma.

Merck's (MRK) Lung Cancer Candidate Faces FDA Rejection

by Zacks Equity Research

The FDA's CRL to Merck (MRK) and its partner Daiichi Sankyo for the patritumab deruxtecan BLA is based on observations made on inspection of a third-party manufacturing facility.

Is Trending Stock AbbVie Inc. (ABBV) a Buy Now?

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.